PDS Implant with Ranibizumab 100 mg/mL

DEVICE2 trials

Sponsors

Hoffmann-La Roche, Genentech, Inc.

Conditions

Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration

Phase 3

Extension Study for the Port Delivery System With Ranibizumab (Portal)

RecruitingNCT03683251

Hoffmann-La RocheNeovascular Age-Related Macular Degeneration

Start: 2018-09-20End: 2029-12-31Target: 1000Updated: 2026-08-31

Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

RecruitingNCT04853251

Genentech, Inc.Neovascular Age-related Macular Degeneration

Start: 2021-12-14End: 2027-08-31Target: 188Updated: 2026-09-02

Related Papers

Port-Delivery-Plattform mit Ranibizumab (PDS) bei Augen mit hoher Injektionslast: Interimsanalyse der Belvedere-Studie bei Patienten mit nAMD

German Medical Science (German Research Foundation)2026-06-17

Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.

2024-08-304 citations

Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development.

2024-08-161 citations